Aanjaneya Lifecare Posts Robust Growth, net up by 75% in Q3, Inches Close To Acquisition

Aanjaneya Lifecare Posts Robust Growth, net up by 75% in Q3, Inches Close To Acquisition

Sets Out To Reach An Ambitious Plan To Reach 500 Crore By 2014

Maharastra , Mumbai, Tuesday 31st Jan 2012 : Mumbai based Mid Sized Indian Pharma major Aanjaneya Lifecare Limited is charting out its expansion plan p0st the robust performance of quarter ended December 31, 2011 with sales zooming to1075 million for the quarter ended December 31, 2011; YoY growth over Q3 FY 2011 of 62% & PAT is Rs.121 million for the quarter ended December 31, 2011; YoY growth of 75% with the overall Results for the 9 months ended December 31, 2011 & the Sales are Rs.3188 million for the 9 months ended December 31, 2011; YoY growth over 9MFY2011 of 44% & PAT is Rs. 357 million for the 9 months ended December 31, 2011; YoY growth of 58%. The Mumbai-based pharma company is engaged in the manufacture of anti-malarial active pharmaceutical ingredients (APIs) and herbal medicines, inhalers, lozenges and animal health products. The company is the world's third-largest manufacturer of quinine salts used in the treatment of malaria. It is also one of the country's largest contract manufacturers of codeinebased cough syrups. The money ( Rs 117 crore) raised by the company through its IPO is being used to build new capacities and for the revamp of its R&D centre. With new capacities to be added in the next 6-9 months, the company aims to expand its operations in the emerging markets of South East Asia, Africa & South & Central America, It also plans to grow its domestic operations in the branded generics segment. The company has a market capitalisation of Rs 612 crore. Aanjaneya Lifecare, a Rs.320 crore plus Mumbai based pharma company, has posted strong financial performance during the third quarter ended December 2011. Its net profit surged by 74.9 per cent to Rs.12.14 crore from Rs.6.94 crore in the corresponding period of last year. Its EBDITA also jumped by 88 per cent to Rs.33.94 crore from Rs.18.05 crore. Its net sale went up by 62.5 per cent to Rs.107.57 crore during the quarter under review from Rs.66.21 crore in the similar period of last year. After the announcement of strong performance, Aanjaneya scrip moved up by Rs.14.95 or over 3 per cent to Rs.503.50 on BSE.

The above background is a clear indication to show that Aanjaneya Lifecare is al set to expand its business both domestic as well as international market. A close scrutiny of Company’s growth record wll reveal that from a modest beginning in the year 2006 till date ( since last 5 years), it has made remarkable growth defying all odds & marching ahead with its growth strategy. Its Visionary Vice-Chairman & Managing Director Dr Kannan Vishwanath who will turn 36 this year is leaving no stones unturned to make a formidable presence in the 68,000 crore Indian pharma market. Aanjaneya Lifecare stunned the biggies in the healthcare sector in the year 2011 by raising Rs 117 crore) raised by the company through its IPO at a time when many analysts viewed as a gambling, however, Dr Kannan proved to the point & lived up to the expectations to its stakeholders. We all know that pharmaceutical business in india is very risky yet lucrative if managed well, Dr Kannan just understood the pulse of the market & launched products that will give high margins. The coming days will be a real testing time as how the Company is poised to take its growth drive & fuel the success mantras.
In an exclusive interview to satya Brahma, Editor-In-Chief of Pharmaleaders & Indian Affairs magazine ( www.pharmaleaders.co.in www.indianaffairs.in , beaming Dr Kannan Vishwanath was quite emphatic when asked about his gameplan & success mantra as he says “ In Healthcare Business, Aanjaneya Lifecare was always focused to what it wanted to do no matter how risky & zigzags the roads are..I am quite optimist that backed by a battery of strong professionals within the company, we are here to mark our mark & provide molecules at an affordable rates. He went out to say that Aanjaneya Lifecare will soon make its foray into some of the biggest markets in the world & reach a magic figure of 500 Crore by the turn of 2014”. He however declined to make any comments on the acquisition front. But sources close to Pharma Leaders reveal that indeed Aanjaneya Lifecare is very close to acquire a domestic pharma company to widen its product basket. The deal could be the game changer for Aanjaneya Lifecare as I will add extra products & market presence”. Although the magnitude of the acquisition is not known despite many attempts to ask the company, but it could well within be 40 to 50 Crore if sources to the Pharmaleaders are to be believed.
For the first nine months of 2011-12, Aanjaneya recorded sales growth of 44 per cent to Rs.318.81 crore as against Rs.221.46 crore and its net profit increased by 58.3 per cent to Rs.35.79 crore from Rs.22.61 crore. EBDITA touched to Rs.88.55 crore from Rs.52.99 crore, registering a growth of 67.1 per cent. The earnings per share worked out to Rs.30.91 on an enlarged equity capital at Rs.12.58 as against Rs.29.70 on an old equity capital of Rs.7.58 crore. The company recently raised about Rs.117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment. Commenting on the financial performance of the Company Dr. Kannan Vishwanath, Vice Chairman and Managing Director of Aanjaneya Lifecare Ltd said,”We are very pleased with our financial results as our company is growing and will continue doing the same in future. The company’s business growth startegy has resulted in the over all good performance which can be seen in the performance for the quarter ended December 31, 2011. The company has performed excellent and it assures the sharesholders that the company will continue performing good in future too”.
A Brief Overview of Aanjaneya Lifecare Limited

Aanjaneya Lifecare Limited ( ALL ) is one of India’s emerging research based integrated pharmaceutical company with established manufacturing & marketing capabilities headquartered in Mumbai India. The product portfolio of the company includes highly Innovative Alkaloids, Anti Malarial APIs & Anti Cancer APIs from Natural Sources & Veterinary APIs. In Finished Dosages we cover important therapeutic areas such as Anti Malarial, Anti Cancer, Erectile Dysfunction, Hormone Replacement Therapy, Anti Obesity, Herbal products & Lozenges for various Therapeutic segments. Our strength lies in an excellent track record of regulatory approvals & ability to produce a broad range of pharmaceuticals and dosages, like solid, semi-solid, liquid, Gels, Ointments & Lozenges & strong R&D capability, with particular expertise in technically challenging products.

In short span of 6 years we have emerged as third largest manufacturer of Anti-malarial Bulk Drugs Quinine salts in world with presence in 61 countries. We have 5 world patents filed for non infringing route of synthesis for manufacturing Anti Cancer APIs. In Formulations We have introduced for first time in India & emerging markets Nicco-Nil (Hard Boiled Lozenges) containing Nicotine for Quitting Smoking . We have a Pipeline of 75 products to be introduced in phases. . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals Our Initial Public Offering in May 2011 was well received & we have been listed in both the premier stock exchanges in India , Bombay Stock Exchange & National Stock Exchange & trading over 40 % premium to our listing price. Aanjaneya Lifecare Introduced for the First Time in Emerging markets of Kenya Tanzania & Dominican Republic Nicco-Nil An OTC product For Quitting Smoking. Introduced 10 products in Lozenges dosage forms which are sugar free & Novel Drug Delivery Systems & available in OTC for Mouth Ulcers ( Ulsacare ) , Prostrate Cancer ( Curcumacare ) , Insomnia ( Relacs) , Appetite enhancers for children ( Apitcatch ) , Arecta Plus ( Erectile Dysfunction ) , Livchek ( Liver Protection ) ,Ezmove ( Mild Laxative) , Natroumune ( Immunity Booster ) & Flukil ( Swine Flu Protector ) . Have invested in Rain Water Harvesting in both our manufacturing facilities & harvest Rain Water in Monsoon for our requirements, further Installed Solar Panels for energy requirements of our utilities, new blocks have been constructed using Eco Friendly recyclable material & The blocks are in process of being rated by LEEDS as Platinum Star . Aanjaneya Lifecare Received the Green Business of the Year Awards at Emerging India Awards held by CNBC TV-18 & ICICI Bank at Macau inNovember 2010 . Aanjaneya Lifecare recently received two prestigious recognitions at 4th Annual Pharma Leadership Summit & Awards 2011. PharmaLeaders, an international bi-monthly magazine & Indo-American Chamber of Commerce, honoured Aanjaneya Lifecare with two prestigious awards “Emerging Pharma Company of Year 2011” & “India’s Most Technically Advanced Manufacturing Facility of the year 2011” at a glittering ceremony in Mumbai held at Hotel Intercontinental at a gala event on Saturday 10th December 2011. The Company has Grown at CAGR of 175 % in last 4 years having state of the Art Facilities which have WHO GMP approval, ISO 9001:2008, ISO 14000 :- 2008 & ISO 22000:2005 accreditation. Aanjaneya Lifecare debuted in the premier stock exchanges of India, Bombay Stock Exchange & National stock Exchange in May 2011 & are being traded at about 40 % premium of listed prices . As part of Corporate Social Responsibility program the company has upgraded the school toilets, the class rooms & roofing of an all Girls high School in Mahad , Maharashtra State India. We have constructed Temporary Sheds & housing arrangement for Stray animals in Monsoon for an NGO IDA (In Defense of Animals ) in Mankhurd – Mumbai.

Dr Kannan Vishwanath
Vice Chairman & Managing Director
Aanjaneya Lifecare Limited

Dr Kannan Vishwanath founded Aanjaneya Lifecare Limited in 2006. He has completed his Chemical Engineering in Pune & Masters & Doctorate of Philosophy in Business Management from University of Azteca. He has over 12 years Experience in Pharmaceutical Industry with expertise in Licensing, Business Development, API, Generics, Finished Dose, Intermediates, marketing, production, distribution, licensing, outsourcing, contract development, formulation development. Patience and Risk Taking are among the motivational factors applied by Dr Vishwanath and they have helped the company to learn from past mistakes and in making better decisions in future. A believer in fair practices, this visionary leader always offers his hand when needed regardless a friend or foe. Dr Vishwanath believes: “when you have a gream , don’t let anything dim it . Keep hoping, keep trying , for Sky is the Limit.

Coming from a very humble beginning with just 40 employees and small manufacturing facility for anti malarial drugs over 6 years ago , Dr Vishwanath has achieved exceptional results through developing and redefining the business roadmap, ensuring differentiation as a competitive advantage and clearly focusing on the brands consumers want and the products consumers need . Anjaneya Lifecare Limited (ALL ) produces & markets a range of pharmaceutical products across the globe . With two facilities in Maharashtra state employing over 300 people the company delivers essential products for every day life under the brands Rankorex, Prosils, DocTor quore, Esyhil, amongst others. The company has over 200 distributors pan India for its Branded Generic products & exports to over 40 countries with sales in excess of 320 crores. Under Dr Vishwanath’s leadership, the marketind, reachersh & product development departments were expanded . The company has been growing at CAGR of 175 % for last 5 years and is now the third largest manufacturer of Quinine salts in world. ALL has received many awards and accolades which recognize its brands and product excellence , such as the Green Business of the year-2011 at Emerging India Awards by ICICI Bank & CNBC TV 18 & voted among the top 100 company in “ India’s Best Companies to Work With -2011 “
PROFESSIONAL SUMMARY
Innovative and results driven leader focused on achieving exceptional results in highly competitive environments that demand continuous improvement. Experience in driving product, process and customer service improvement while building partnerships with key business decision makers
Consistently increased production, reduced operating costs and improved product quality by utilizing world class manufacturing concepts ( lean manufacturing six sigma, theory of constraints etc ) to optimise & rationalize manufacturing processes and supply chain networks Known for building and motivating cross functional teams that exceed corporate expectations.
PROFESSIONAL EXPERIENCE

Promoter & Managing Director
Aanjaneya Lifecare Limited (1/2006 - Present)
Mumbai India.
India’s largest manufacturer of Quinine salts
• Transitioned company transformation from a family owned business to a merger and acquisition and management buyout of a formulation company & integrating business
• Drove he operational planning and successful execution for doubling product lines manufacturing capacity to exploit market growth opportunities.
• Achieved two site turnarounds within two years , bringing operational metrics to baseline standard , while maintaining and improving permanent priorities of safety quality service appearance and people
• Leadership and aggressive development of the company's Formulations business. Identification of market blockbusters and strategies for organic and inorganic growth of formulation segments.
• Drive the company's initiative to become a formulations driven company with a clear focus of making the Formulations business account for 60% of the company's Revenue.
• Building winning teams and driving aggressive growth not just in terms of Year on Year growth but in terms of market shares in the segments the company chooses to work in.
• Sustain and grow the existing pipeline and develop the pipeline for the future. Ability to separate the winners from the losers and dropping losers early in the game is key.

Director (International Sourcing, Business Development & Planning)
BENZOCHEM LIFESCIENCES PVT LTD (1999-2006)
ISO 90001:2000.ISO 14001:2004 & India leading manufacturer of oncology APIs
• Was responsible for a Team of 50 people with $ 10 million budget including supply chain functions two sites, distribution network all inclusive from product conception, procurement, planning through quality and operations to customer delivery.
• Presented and gained approval from the board of directors and executed capital expenditure of 4 million USD with ROI of 5 years
• Developed an effective blend of best practice, teamwork-based culture combined with execution of organizational goals, strategies and measures, which supported the turnaround of the company from near bankruptcy to a stable . rapidly growing business
• Created a cohesive product supply leadership team and provided one-on-one coaching capitalizing on each person’s strengths to deliver high customer satisfaction and quality levels at the lowest total delivered cost.
• Developed communicated and educated product supply leaders and employees on the key profit drivers and tied performance, rewards and recognition to those results. This resulted in cost savings of over 250,000 USD per year.
• Led a core team of engineering research and development and marketing employees who redesigned and implemented upgraded product line up with achieved improved customer satisfaction , superior product
EDUCATION
MIT PUNE- MAHARASHTRA India.
Bachelor of Engineering
Asia-E-University .
Masters in Business Administration
IIRM – Univerisity of Azteca
Doctor of Philosophy in Business Management
International University of Vienna
Honorary Doctorate
PUBLICAT IONS AND RESEARCH
The Study of Individuals Organizational & Environmental Determinants of Innovation by Kannan Vishwanath
Co-Authored & published patents of Tran’s dermal formulations
A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF METHANDIEONE AND BOLDENONE FOR SAFE DRUG DELIVERY 212673 - 23/MUM/2005

A NOVEL HYDRO ALCOHOLIC GEL AND/OR CREAM FORMULATION OF TOPICAL STEROID OF TRENBOLONE ACETATE AND 212674 - 22/MUM/2005

A NOVEL TRANSDERMAL GEL AND/OR CREAM FORMULATION
212676 - 19/MUM/2005

A NOVEL HYDRO ALCOHOLIC GEL AND /OR CREAM FORMULATION OF NANDROLONE DERIVATIVES
212692 - 20/MUM/2005

A NOVEL HYDRO-ALCOHOLIC GEL AND/OR CREAM FORMULATION OF ANDROSTEN -17-01-3-ONE DERIVATIVES FOR SAFE DRUG DELIVERY SYSTEM
212752 - 21/MUM/2005
MEMBERSHIPS
 Indo American chamber of Commerce
 Indo African chamber of Commerce
 Indo German Chamber of Commerce
 Indian Merchant Chambers
AWARDS & HONORS

The European Quality Award 2008 on Behalf of Aanjaneya Biotech Pvt Ltd

The Bizz Award 2008 on behalf of Aanjaneya Biotech Pvt Ltd

OTHER ACCOMPLISHEMNENTS, RESPONSIBILITIES & PARTICIPATION
Community Service Projects:
In Defence of Animals
Provided temporary shelters for 100 animals during monsoon Season. Donated an ambulance for emergency situations for animals at centre in Mumbai India

Price Control of Medicines are detrimental for India’s Healthcare Growth Story & Drives – Kewal Handa, MD, Pfizer & Wyeth India.

Price Control of Medicines are detrimental for India’s Healthcare Growth Story & Drives – Kewal Handa, MD, Pfizer & Wyeth India.
Health Insurance & Availability should be the focus & not the Govt’s Draft Policy. Canada & Philippines growth is due to non-Price Control.

Maharashtra, Mumbai, Friday 6th January 2011 : Union Health Ministry's plan to bring 348 drugs of the National List of Essential Medicines (NLEM) under price control is facing stiff resistance from the pharma industry. A close scrutiny will reveal that around 75% of the industry will come under price control in case the draft National Pharmaceuticals Pricing Policy (NPPP, 2011) is pursued in its present form. Cautioning that it will cripple the pharma sector, Kewal Handa, said the government estimates that the new policy would bring 60% of the Rs 48,200-crore domestic formulation industry under the pricing control compared to 20% earlier. The ministry says, more than 300 drugs were under the Drug Price Control Order (DPCO) in the early 1980s that was subsequently reduced to 140 in 1987. At present, prices of only 74 bulk drugs and formulations, containing any of these scheduled drugs, are under the price control regime. Once a medicine is brought under DPCO, it cannot be sold at a price higher than that fixed by the government. NLEM has 348 medicines that cover 489 formulations, including 16 fixed-dose combinations. These drugs are considered to be adequate to meet the common contemporary health needs of the general population.
Addressing at 4th Annual Pharmaceutical Leadership Summit & Awards 2011 in Mumbai (www.pharmasummit.in ) organized by Asia’s leading Pharma bi-monthly Pharma Leaders Magazine ( www.pharmaleaders.co.in ) , Kewal Handa, Managing Director of Pfizer & Wyeth, Handa said Price Control has become redundant & is unnecessary & instead it will create more troubles & hit the healthcare Industry. In an exclusive Keynote address Handa said The DPCO 1995 has been there for more than a decade, what is the learning of all these in the past, the number of players that were there in DPCO has been substantially come down & the number of molecules have also drastically come down. The number of new introductions in the old DPC0 ( Drug Price Control Authority) are less than that which are there in outside purview of DPCO. Ironically One Third of the products that are there in 1995 have gone to China. Therefore price control does not work & If you look at the global experiences, you will find the correct assessment. Lets look at Canada when the price control was introduced, in a span of three years the Research & Development ( R & D) came down by 50%. Look at Brazil, you will find there also similar experience . And the prices in Philippines are reduced almost by 50 % & who got benefited of all these exercises, the Branded Generic players, the movers from Generics to Branded Generic Players. Now we have a similar experience in India, which is difficult to understand, as the reason given to reduce the price is quite disturbing . If you look at the history of price rises in India since last five years you will see clearly that the price rise is not more than 2% in DPCO as well as in the non DPCO Categories. And if you look at the competition, it is very intense & fierce , for every molecule we have not less than 50 players competing & if that’s the scenario in india where the prices are lowest in the world, is there the need to reduce the prices? Is there a need to bring everything to a single conversant price?? do you want to accommodate our healthcare industry. Do you want to play with the lives of the people cautions Kewal Handa.
He goes on to say that today we need a different treatment, we need to increase our accessibility, we need to increase our availability & more importantly we need to provide Healthcare Insurance to the needy who cant afford to medical treatment . Almost 60% of Indian population can afford to have mobile phones & there is only 15 % of Indian population who has health insurance & this 60% of people who own mobile phones takes the health coverage & the rest are denied of their basic needs& on the light of the above I don’t think so there will be any need for price control or price reduction. All that you need is critical mass coverage. We need to think & debate how to get this critical mass so that chronic diseases can be covered so that middle class population can avail of affordable medicines. The large chunk of Indian population should get access to basic medicines. He concludes saying “I believe that discussion should be on partnership & Accessibility & india has a very good track record of Price Control which is self regulator. I think the Govt should leave it this method as it is”.

Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011

Ranbaxy Global Consumer Healthcare & Aanjaneya Lifecare Declared Winners In “Neutraceutical Segments” & “Company Of The Year Award” Respectively at 4th Annual Pharmaceutical Leadership Awards 2011
Kewal Handa Of Pfizer & Aditi Kare Of Indoco Are Business Leaders While Pfizer, Abbott, GSK, Microlabs, Elder Pharmaceuticals, Fortis, Bharat Biotech, Adriot Are Biomed Among Those Win The Race In Important Categories.
Mumbai : 16th December 2011 : 4th Annual Pharmaceutical Leadership Summit & Awards 2011 ( www.pharmasummit,in ) organized by India’s leading bi-monthly Pharma Magazine ( www.pharmaleaders.co.in ) & IACC culminated in high notes as 23 categories of various Nominations were declared Winners in a sequel to 60 days of votings & Juries final verdict. Among those Companies & Individuals who were declared Winners for their outstanding performance in fiercely competitive India Pharma Market are 1.Business Leader of the Year 2011 : Mr KewalHanda, Managing Director, Pfizer India Ltd. 2.Business Woman of the Year 2011 ( Gen-Next Pharma Leader), MrsAditi Kare Panandikar, Whole Time Director, Indoco Remedies Ltd. 3.Dynamic Entrepreneur of the Year 2011: Dr Krishna Ella, CMD, Bharat Biotech International Ltd. 4.Pharma OTC Company of the Year 2011: Ranbaxy Global Consumer Healthcare. 5.India’s Most Admired Nutrition &Neutraceuticals of the Year 2011, Revital Woman & Abbott Healthcare Pvt Ltd. 6.Company of the Year 2011: Venus Remedies Ltd.7.Pharma CSR Organisation of the Year 2011: Ranbaxy Labs Ltd. 8.Pharma Professional Of the Decade 1.Dr Ajit.V.Dangi, CEO & President, Danseen Consulting. 2. Mr RanjitShahani, Vice-Chairman & MD, Novartis India Ltd,3. Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. 9.Brand of the Year 2011: Revital&Volini. 10.Innovative R & D Company of the Year 2011, Bharat Biotech International Ltd. 11.Emerging Brand of The Year :B-COLEN RANGE of Galpha Labs. 12.India’s Most Admired Foundation in Social Innovation: Right to Vision Programme of Wockhardt Foundation. 13.Pharma Achiever of the year in SME,Dr. Rege's Laboratories.14.India’s Most Admired Company in Blood and Biological Products 2011,Synergy Diagnostics Pvt Ltd. 15.India's Most Admired Pharma Company 2011: Microlabs Ltd. 16.India's Most Watched Company of the Year 2011, Elder Pharmaceuticals Ltd,17. Emerging Company of the Year 2011,AanjaneyaLifecare Ltd. 18.India’s Most Admired Company in Exports 2011:Genom Biotech Pvt Ltd. 19.Research Scientist of the Year 2011: Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 20.Multinational Company of The Year 2011. ( Joint Winners)1. Pfizer India Ltd, 2. Glaxo SmithKline Pharmaceuticals Ltd.21.India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. 22.Biotech Research Company of The Year 2011. Adroit Biomed Ltd.23.India’s Most technically & scientifically advanced Pharmaceutical Manufacturing unit of the year 2011. Aanjaneya Lifecare Ltd.
Speaking on the Award Declarations, Mr Satya Brahma, Chairman of Network 7 Media Group said “ Pharmaleaders salute these shining stars who bagged these coveted Awards by a rare display of achievements & performed under a changed healthcare scenario”.
With an aptly theme of Generation Next Indian Pharma Leaders, Billionaire Minds, Drivers for Growth at 4th Annual Pharmaceutical Leadership Summit & Awards 2011, veterans of the India’s Healthcare Industry debated on many topics that grappled Indian Healthcare segments. In an opening address, Mr Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders Magazine ( www.pharmaleaders.co.in ) said “ Indian Healthcare Industry has emerged out as a global super Power & has displayed remarkable display of manufacturing excellence & quality medicines & is way ahead of many developed nations, it is only a matter of time that it will overtake China in coming days, he added. He also lamented at Policy Makers & Authorities for slow decision making process specially in the context of Draft Pricing Policy & FDI in Healthcare Sector & urged the Ministry to hear the voices of the healthcare industry”.
Amonth those who addressed at Asia’s Biggest Leadership Meet are Mr. S. Krishnakumar (KK), Market Leader ( Life Sciences)Future Steps ( A Korn/Ferry Company, Dr Lalit S Kanodia, President Indo-American Chamber of Commerce, (IACC), Western Region, & CMD, Datamatics Ltd. Should drug prices be regulated?Mr. Kewal Kanda, MD, Pfizer India Ltd.` India – An Emerging Pharmaceutical Powerhouse , Dr Ajit V Dangi, Board Chairman, Fulford India Ltd. President & CEO, Danseen Consulting. Dr. Rashmi Barbhaiya , CEO and Managing Director - Advinus Therapeutics Ltd “From Scientist To CEO. The vision: Create a Pharmaceutical company focused on discovering and developing the next generation of high end commercialized medicines.Recent Advancements in Blood & Biological products :Mr Sanjay Bawsay, Managing Director, Synergy Diagnostics Pvt Ltd. Human biotechnology research in India, with emphasis on the BBIL story.Mr. Sai D Prasad, Project Manager - Rotavirus Vaccine Project and Vice President - Business Development. Are FDI & Price Control Policy in Indian Pharma Sector deterrent for growth & Globalize Indian Healthcare Industry. Mr. Shashikant B. Shinde ,Whole Time Director, AanjaneyaLifecare Ltd. Differentiate or Die - Pharmaceutical Industry in India. Mr.DeepakNaik, Managing Director Health 'N' U Therapeutics Pvt. Ltd. MrAnand Desai, National President, IACC & Managing Partner, DSK Legal : Do Pharmaceutical Companies Have Debt Crisis Strategy?. A Legal Perspective. Mr Narayan Gad, CEO, Formulations, Panacea Biotech Ltd. Moving Beyond the Healthcare Debate : The Transformative Trends That Will REALLY Define Our Future. Pharma’s Value Proposition - How The Industry Must Change. Perspectives On Current Industry Challenges .Mr. Sunil Madhok, Director, Business Development, Pfizer India Ltd.
More details of the post event are available on requests at editor.in.chief@pharmaleaders.co.in .

Watch Pfizer Chief Kewal Handa As He Speaks On His Perspectives of The Controversial Draft Pharma Pricing Policy

Indian Healthcare Industry’s leading voice & one of the most respected name in the pharmaceutical sector, Mr Kewal Handa who strategies world’s leading drugmaker Pfizer in Indian operation will be speaking exclusively via televised tape on how The Centre’s decision to decontrol drug prices would take essential medicines beyond the reach of the common citizen. The controversial policy has been a bone of contention in the industry as there are no takers as the key pharma firms flay ‘populist' draft policy. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank.Patented drugs are not defined in the drugs (Price Control) Order, 1995 (DPCO, 1995). Under the provisions of the DPCO, 1995, prices of 74 scheduled bulk drugs and the formulations containing any of these scheduled drugs are controlled. National Pharmaceutical Pricing Authority (NPPA) fixes or revises prices of scheduled drugs / formulations as per the provisions of the DPCO, 1995. Anti-cancer medicines are non-scheduled drugs, i.e. not covered under DPCO, 1995. In respect of non-scheduled drugs, manufacturers are at liberty to fix the prices by themselves without seeking the approval of Government / NPPA. Department of Pharmaceuticals has prepared a draft National Pharmaceutical Pricing Policy 2011 (NPPP-2011) based on the criteria of essentiality and requirements as stipulated by the Ministry of Health & Family Welfare. The draft Policy envisages bringing the National List of Essential Medicines (NLEM) – 2011 and associated medicines under price control. The draft NPPP-2011 has been circulated among the concerned Ministries/Stake holders asking them for the feedbank. This information was given by the Minister of State for Chemicals and Fertilisers, Srikant Kumar Jena in a written reply in the Lok Sabha recently.
Handa speaks exclusively at the 4th Annual Pharmaceutical Leadership Summit 2011(www.pharmasummit.in ) organised by Pharmaleaders ( www.pharmaleaders.co.in ) to be held in Mumbai ob 10th December 2011 via Careworld TV. Mr Handa has strong reservations on the proposed policy as he feels that this will have detrimental effect on the healthcare sector. Kewal Handa is Managing Director, Pfizer Limited, the world’s No.1 pharmaceutical company that discovers and develops break-through drugs, provides information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines, consumer products; and is a global leader in corporate responsibility. Under his leadership, the company is now aggressive in its growth plans and has launched several new products.
Kewal is a reputed industry expert who takes the lead on key issues that concern the pharmaceutical sector. As Vice President of the Organisation of Pharmaceutical Producers of India (OPPI), he has been at the forefront of the industry’s efforts to resolve issues pertaining to the pharmaceutical sector. He is also the Chairman of DPCO & Taxation Committee of OPPI. He has recently been appointed as the President of All India Management Association and is a committee member of various industry bodies in the country. Kewal was awarded the ‘India CFO 2004 – Excellence in Finance in an MNC’ by International Market – Assessment Group and has recently won the Bharat Shiromani Award. A qualified Management Accountant and Company Secretary, and with a Masters Degree in Commerce from Sydenham College, Mumbai, Kewal has completed the Pfizer Leadership Development Program from Harvard University, the Senior Management Development Program from IIM, Ahmedabad. He has also done a course on Marketing Strategy from Columbia Business School. Mr. Handa is also the Managing Director of Wyeth Ltd.

Management Guru Dr Ajit Dangi to address on India : An Emerging Powerhouse at 4th Annual Pharma Summit 2011

India is also set to become global hub for clinical trials sector. Today India is the most favored destination, fast becoming a signification hub for conducting global clinical trials, contract research, bio-technology. In terms of cost efficiency India is better, as the cost of conducting a trial here is lower by 50-60% than in the United States or the European Union. Key strategic drivers for profitable growth , Including enabling business environment, leveraging Intellectual property as a competitive strategy, building international brands , inorganic growth thru` mergers , acquisitions and alliances, changing paradigm in Pharmaceutical R&D, Biosimilar and OTC Opportunities , making India a Destination of Choice in CRAMS by moving from cost arbitrage to intellectual arbitrage and capitalizing on healthcare reforms in the developed world is what veteran HealthcareManagent Guru is going to address at 4th Annual Pharmaceutical Leadership Summit 2011 at Hotel Lalit on 10th December 2011. India is one of the most significant emerging markets for the global pharmaceutical industry. Moreover, India is expected to join the league of top 10 global pharmaceuticals markets in terms of sales by 2020 with the total value reaching US$ 50 billion, according to a report by PricewaterhouseCoopers (PwC). The domestic pharma market is expected to grow at a CAGR of 15 to 20 percent to reach a value anywhere between USD 50 and 74 billion by 2020, says a PwC report titled ‘India Pharma Inc: Enhancing Value through Alliances & Partnerships’.

The Indian pharmaceutical market is expected to grow to US$ 55 billion by 2020 from the 2009 levels of US$ 12.6 billion, as per a McKinsey & Company report titled “ India Pharma 2020: Propelling access and acceptance realising true potential”. The industry further holds potential to reach US$ 70 billion, at a CAGR of 17 per cent. India’s pharmaceutical industry constitutes of about 8 per cent of the world’s pharmaceutical production. Over the last couple of years, Indian pharma companies have been increasingly targeted by multinationals for both collaborative agreements and acquisition, as per a Espicom report titled, “The Pharmaceutical Market: India Opportunities and Challenges”. The US$ 12 billion valued pharmaceutical industry in India is expected to grow at an annual compound annual growth rate (CAGR) of 10-11 per cent. The industry spends around 18 per cent of its revenue on research and development (R&D).
India’s exports of drugs, pharmaceutical & fine chemicals stood at US$ 9.26 billion during April 2010–Feb 2011, up 16.15 per cent as compared to US$ 7.97 billion in the same period during the previous year. India’s exports has recorded a growth rate of over 20.07 per cent, during the period of the two financial years in the study, the exports to rest of the world has grown by 9 per cent, according to DGCIS data from Pharmexcil Research. India and Russia signed a memorandum of understanding (MoU) last year. Another will be signed in December 2011, as per Mr Devendra Chaudhry, Joint Secretary, Department of Pharmaceuticals. Indian pharma companies export drugs worth US$ 600 million to Russia every year. Pharma sector accounts for the largest Indian export to Russia. The drugs and pharmaceuticals sector attracted foreign direct investments (FDI) worth US$ 4.89 billion between April 2000 and August 2011, according to the latest data published by Department of Industrial Policy and Promotion (DIPP). Indian pharmaceutical market is predicted to grow to US$ 55 billion by 2020 from US$ 12.6 billion in 2009, according to a report by McKinsey. On back of a high middle-class population base, improvements in medical infrastructure and the establishment of intellectual property rights, the Indian pharma industry is estimated to grow manifold. Generics will continue to dominate the market while patent-protected products are likely to constitute 10 per cent of the pie till 2015, according to McKinsey report ‘India Pharma 2015 - Unlocking the potential of Indian Pharmaceuticals market’. Moreover, as per a press release by research firm RNCOS, the report titled ‘Booming Generics Drug Market in India'. The report further projects the Indian generic drug market to grow at a CAGR of around 17 per cent between 2010-11 and 2012-13. India tops the world in exporting generic medicines worth US$ 11 billion. Currently, the Indian pharmaceutical industry is one of the world's largest and most developed, according to Mr Srikant Kumar Jena, Union Minister of State for Chemicals and Fertilisers. The Pharma market world over will experience substantial changes. Asia-Pacific region is emerging as the fastest growing pharmaceutical market in a recent years. Today, Indian Pharma business is emerging as a global powerhouse with rich pipeline of various products, is becoming 3rd Pharma super power in the international level, despite the current economic slowdown pharmaceutical R&D is increasing mode in India. Industry Insights, reports that the Indian pharmaceutical market, is growing at almost 10 to14 % and valued at Rs.1,00,000 crore currently, it could see the almost double figure in next 5 years. Today Indian Pharma segment will stands at the cusp of a world major out put; exports and contract manufacturing business are growing at 10 % Per anum, and it will contribute to achieve the promised growth in coming years. The Indian pharmaceutical companies export their products (Drug intermediates, APIs, Finished Dosage Formulations, Bio Pharmaceuticals) to more than 200 countries around the world (including highly regulated markets of USA, West Europe, Japan and Australia). 40% of the world’s bulk drug requirement is met by India. As multiple global segments are available for Indian Pharma companies: Such as Pharma manufacturing, drug discovery, research, clinical outsourcing, marketing, and etc. With the increased presence of multinational companies, the Indian pharmaceutical sector is flourishing with multiple opportunities, even the Indian companies are revamping their R&D facilities to comply with World Trade Organization’s Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) agreement and recognized product patents with the amendment of the Indian Patent Act in January 2005.

Steve Hamper
Editorial Director - Pharmanewsprwire
For Registration :
Noble Services
Dimple Arcade, 3rd floor, 314, Asha Nagar,
Kandivali east, Mumbai - 400101. Mr. Sohail Shaikh - +91(0)8888117599
Mr. Mohsin Darvesh - +91(0)810-8120-436
Email : pharmasummit2011@webnoble.co.in
Web : http://www.pharmasummit.in

Massive Voting At 4th Annual Pharmaceutical Leadership Award Nominations 2011 Could Spring Surprise Winners

Massive Voting At 4th Annual Pharmaceutical Leadership Award Nominations 2011 Could Spring Surprise Winners
Aditi Kare Of Indoco Remedies With Dr Manu Chaudhary Of Venus Remedies In Close Race For Coveted Business Woman Of The Year. Pfizer, GSK, Elder Pharma, Abbott, Sanofi Aventis, Sun Pharma, Aanjaneya Lifecare Etc Are Hot Favorites At Leadership Awards 2011
Mumbai : 16th November 2011 : As the date of 4th Annual Pharmaceutical Leadership Awards 2011 inch closer to the event date of 10th Dec 2011, the competition for Nominations selected in 25 important categories (www.pharmasummit.in ) getting more & more competitive as large number of Pharma professionals to the tune of 1 million are casting their votes to chose their favourite companies & business leaders. Organized by Pharmaleaders Magazine(www.pharmaleaders.co.in ) & Indo-American Chamber of Commerce ( IACC), 4th Annual Pharmaceutical Leadership Summit attempt to raise burning issues confronted by the Industry. While The Summit will debate on Gen-Next Indian Pharma Leaders with specific emphasis on controversial FDI policy of the Govt as well as Draft Bill of Pricing, The Event is touted to be the biggest conglometer of south-East Asia’s meeting points where Who’s & Who’s of the Healthcare fraternity will assemble to witness to gain the ultimate leadership experience. More than 250 top executives have blocked their calendar for this mega meet.
Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, these were first produced by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance and research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PBT Awards in India and expanded to recognize global corporate citizenship and individual achievements.As PBT Magazine was discontinued, the task was taken up by the Management of Pharma Leaders Magazine. Over the Years, the awards was re-evaluated and recast to focus more on scientific accomplishments in industry and academic pharmaceutical research. The awards have been presented and at a sold-out gala award night. Since the institution of Leadership Awards, over 200 industry executives and leading academic scientists from around the world have been honoured. Winners have been selected via various processes & judging are based on information provided by the nominees. With the three tier voting process in Email, SMS & Juries verdict, the stage is set for the nominees such as 1. Business Leader of the Year 2011. Dr Habil F Khorakiwala, Chairman, Wockhardt Ltd (Vote HFK to+ 91 9892108169). Mr. Glenn Saldanha, Chairman & MD (Vote GS to+ 91 9892108169). Kewal Handa, Managing Director, Pfizer & Merck Ltd. (Vote KH to+ 91 9892108169). 2. Business Woman of the Year 2011 ( Gen-Next Pharma Leader). Mrs Vinita Gupta, Lupin LTD (Vote VG to+ 91 9892108169). Mrs Aditi Kare Panandikar, Director, Indoco Remedies Ltd (Vote AK to+ 91 9892108169). Ms. Nandini Piramal, Executive Director, Piramal Healthcare Limited, (Vote NP to+ 91 9892108169). 3. Dynamic Entreprenuer of the Year 2011. Dr. GSK Velu, Founder, Trivitron Group of Companies (Vote GV to+ 91 9892108169). Mr K Raghavendra Rao, Chairman & Managing Director,Orchid (Vote KR to+ 91 9892108169). Dhirendra Kumar, Managing Director,Camson Biotechnologies Ltd,(Vote DK to+ 91 9892108169). Dr Krishna Ella, CMD, Bharat Biotech International Ltd ( Vote KE to ++ 91 9892108169). 4.Pharma OTC Company of the Year 2011. Alkem Health Foods (Vote AH to+ 91 9892108169). Elder Pharmaceuticals Ltd (Vote EP to+ 91 9892108169). Abbott Nutrition (Vote AN to+ 91 9892108169). Ranbaxy Ltd ( Vote RAN to – 91 9892108169). 5.India’s Most Admired Nutrition & Neutraceuticals of the Year 2011. Apex Laboratories Ltd (Vote APEX to+ 91 9892108169). Abbott Nutrition (Vote AB to+ 91 9892108169). British Biological (Vote BB to+ 91 9892108169). Novartis India Ltd. (Vote NI to+ 91 9892108169). 6. Company of the Year 2011. Twilight Litaka Pharma Ltd. (Vote TL to+ 91 9892108169). Mankind Pharma Ltd (Vote MP to+ 91 9892108169). Pfizer Ltd (Vote PL to+ 91 9892108169). Abbott India Ltd (Vote LL to+ 91 9892108169). 7.Pharma CSR Organisation of the Year 2011. Ranbaxy Ltd (Vote RL to+ 91 9892108169). Wockhardt Foundation (Vote WF to+ 91 9892108169). Zydus Cadila Ltd (Vote ZC to+ 91 9892108169). Piramal Enterprises. (Vote PE to+ 91 9892108169). 8. Pharma Professional Of the Year 2011 ( No Voting). Dr Kamal Sharma, MD, Lupin Ltd. Dr Ajit V Dangi, President & CEO, Danssen consulting. Mr Ranjit Shahani, Vice Chairman & MD, Novartis India Ltd. 9. Lifetime Achievement Award of 2011 ( No Voting). J.B.Mody, Chairman J.B.Chemicals & Pharmaceuticals Ltd. Pankaj Patel, CMD, Zydus Cadila Ltd. Deepak Pahwa, Chairman, Pahwa Enterprises.10. Brand of the Year 2011. Revital (Vote RE to+ 91 9892108169). Taxim (Vote T+ 91 9892108169). Becosule (Vote BE to+ 91 9892108169). Voloni (Vote VO to+ 91 9892108169). Corex . ((Vote CO to+ 91 9892108169). 11.Innovative R & D Company of the Year 2011. Bharat Biotech International Ltd. (Vote BBIL to+ 91 9892108169). Glenmark Pharmaceuticals Ltd. (Vote GPL to+ 91 9892108169). Zydus Cadila Ltd. (Vote ZC to+ 91 9892108169). Cipla Ltd. (Vote CL to+ 91 9892108169). 12.India's Most Admire Surgeon Of the Year 2011 ( No Voting). Dr Devi Shetty, Chairman, Narayana Hrudayalaya. 13.India's Fastest growing Pharmacy Retail chain 2011. Trust Chemist & Druggist Ltd. ((Vote TC to+ 91 9892108169). Hetero Pharmacy Ltd. ((Vote HP to+ 91 9892108169). Apollo Pharmacy. ((Vote AP to+ 91 9892108169). Religare Pharmacy. ((Vote RP to+ 91 9892108169). 14. Transformational Pharma Leader of the Year 2011 ( No Voting). Dr Surinder Singh – Drug Controller General of India. 15. Excellence Innovators in Blood and Biological Products of the Year 2011. Synergy Dignostic Pvt Ltd. ((Vote SD to+ 91 9892108169). El-Shaddai Biologicals Ltd. ((Vote EB to+ 91 9892108169). VHB Lifesciences Ltd. ((Vote VL to+ 91 9892108169). 16.India's Most Admired Pharma Company 2011. GSK Ltd ((Vote GSK to+ 91 9892108169). Novartis India Ltd. (Vote NIL to+ 91 9892108169). Abbott India Ltd. (Vote ALI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169). 17. India's Most Watched Company of the Year 2011. Bliss GVS Pharma ((Vote BGV to+ 91 9892108169). Novartis India Ltd. (Vote NL to+ 91 9892108169). Abbott India Ltd. (Vote AI to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). 18.Emerging Company of the Year 2011. Aanjaneya Lifecare Limited ((Vote ALL to+ 91 9892108169). Bliss GVS Pharma . (Vote BGPL to+ 91 9892108169). Lincoln Pharmaceuticals Ltd. (Vote LPL to+ 91 9892108169). Venus Remedies Ltd. (Vote VRL to+ 91 9892108169). Duraent Bilogicals ltd. (Vote DBL to+ 91 9892108169). 19.India’s Most Admired Company in Bulk drugs 2011. Hetero Drugs Ltd ((Vote HD to+ 91 9892108169). Aarti Drugs Ltd . (Vote AD to+ 91 9892108169). Parabolic Drugs Ltd. (Vote PDL to+ 91 9892108169). Aurobindo Pharma Ltd . (Vote APL to+ 91 9892108169). 20. India’s Most Admired Company in Exports 2011. Ipca Labs Ltd. ((Vote IL to+ 91 9892108169). Shreya Life-Sciences Ltd (Vote SLS to+ 91 9892108169). Genom Biotech Ltd . (Vote GB to+ 91 9892108169). Glenmark Ltd. (Vote GL to+ 91 9892108169). Sun Pharmaceuticals Industries Ltd.(Vote SPIL to+ 91 9892108169).21. Research Scientist of the Year 2011. Dr. Rashmi Barbhaiya, MD & CEO, Advinus Therapeutics Pvt Ltd. 22. Multinational Company of The Year 2011. Abbott India Ltd (Vote ABBT to+ 91 9892108169). Pfizer India Ltd . (Vote PIL to+ 91 9892108169). Gsk Ltd (Vote GSK to+ 91 9892108169). Sanofi Aventis. (Vote SAL to+ 91 9892108169). 23. India’s Most Admired Hospital Chain 2011. Fortis Healthcare Ltd. (Vote FH to+ 91 9892108169). Appolo Healthcare Ltd . (Vote AHL to+ 91 9892108169). Max Healthcare Ltd (Vote MAX to+ 91 9892108169). Wockhardt Hospitals . (Vote WH to+ 91 9892108169). 24. Biotech Research Company of The Year 2011. Samarth Pharma Ltd. (Vote SPL to+ 91 9892108169). Indegene Lifesystems Pvt. Ltd (Vote ILP to+ 91 9892108169). Serum Institute of India (Vote SIP to+ 91 9892108169). Avesthagen Limited (Vote AVS to+ 91 9892108169). in 25 categories will be tested & voted.
Registration Contacts for Partcipation :
Noble Services
Accord Group of Companies
Dimple Arcade, 3rd floor, 314, Asha Nagar,
Landmark – Behind Sai Dham Mandir.
Kandivali east, Mumbai – 400101.

Mr. Sohail Shaikh - 08888117599
Mr. Mohsin Darvesh - 0810 8120 436
Email : pharmasummit2011@webnoble.co.in
Web : www.pharmasummit.in

Aanjaneya Lifecare closes on its Acquisition Drive

Aanjaneya Lifecare closes on its Acquisition Drive


Indian Healthcare Sector may soon see Acquisitions in SME sectors as partnership & collaboration will rule the markets. Aanjaneya may acquire a domestic formulation unit to fuel its growth engine.


Maharastra, Mumbai, Tuesday,15th November 2011. Mumbai Based Pharmaceutical Major Aanjaneya Lifecare (BSE code (533412), the largest Quinine producers in world is yet again on the news. Sources close to Pharmaleaders (www.pharmaleaders.co.in ) reveal that Aanjaneya Lifecare is on the final stage of negotiations with a domestic formulation unit to widen its product baskets. Market is abuzz as the news of Aanjaneya posted a rapid strides in its balance sheet with Results for the half year ended for the second quarter ended September 30, 2011, the revenue of the company rose by 39% to Rs 1109 million from Rs 799 million for the same period last year. With this, the total revenue during the first half rose by 36% to Rs 2112 million & the net Profit for the second quarter increased 46% to Rs123 million from Rs 84 million for the same quarter of the previous fiscal year. With this the net profit for the first half of the current fiscal shot up by 51% to Rs. 236 million as against Rs. 156 million for the corresponding period of last year.
If the statement by the Board Chairman Dr Kannan to be believed while addressing the AGM “Our Company has showed an impressive growth in the current year and we promise our investors and stakeholders that we will continue to do the same in future” is to be understood in the right context, one can clearly say that Aanjaneya with focus on anti-malarial, and finished dosage forms (FDFs), has zeroed on a domestic unit with presence in cough cold, pain management segment. It is quite evident as the company in last six months was looking at some established Brands into its product baskets. The size of the Acquisition & deal value & the acquiring company is believed to be kept in top secret as many attempts by Pharmaleaders to reach out the company failed & calls remain unanswered. The News, if to be believed in right context, though unconfirmed officially, could be a game changer for Aanjaneya Lifecare given the aggressive plans the company is looking at to expand.

The company recently raised about Rs. 117 crore from its IPO and the funds are being used to built new capacities alongwith the refurbishing of Research & Development centre. The new facilities being created as part of CAPEX are using eco friendly, recyclable material and will be rated by LEEDS once completed, company sources informed. The Facilities being established will comply with the latest European & US guidelines. With new capacities to be added in next 6 to 9 months the company will be expanding operations in emerging markets of South East Asia, Africa & South & Central America and its domestic operation in branded generics segment.

The Author is Editor-In-Chief of Pharmaleaders Magazine. He can be reached at satya.brahma@pharmaleaders.co.in